{"nctId":"NCT00788710","briefTitle":"A Study of MK0663/Etoricoxib for Post-Abdominal Hysterectomy Surgery Pain (0663-097)(COMPLETED)","startDateStruct":{"date":"2008-10"},"conditions":["Acute Pain Following a Total Abdominal Hysterectomy"],"count":430,"armGroups":[{"label":"Etoricoxib 120 mg","type":"EXPERIMENTAL","interventionNames":["Drug: etoricoxib (MK0663) 120 mg"]},{"label":"Etoricoxib 90 mg","type":"EXPERIMENTAL","interventionNames":["Drug: etoricoxib (MK0663) 90 mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Comparator: Placebo"]}],"interventions":[{"name":"etoricoxib (MK0663) 120 mg","otherNames":["Arcoxia"]},{"name":"Comparator: Placebo","otherNames":[]},{"name":"etoricoxib (MK0663) 90 mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients 18 years or older in generally good health who are scheduled to have a total hysterectomy and who are willing to limit alcohol consumption\n\nExclusion Criteria:\n\n* Patient is allergic to the study drug, other cyclooxygenase-2 (COX-2) inhibitors/nonsteroidal anti-inflammatory drugs (NSAIDS), ibuprofen, morphine, or oxycodone or has hypersensitivity to aspirin or other NSAIDS\n* Patient has uncontrolled high blood pressure\n* Patient has a history of drug and/or alcohol abuse within the last 5 years\n* Patient has taken part in another investigational study within 4 weeks of the start of study\n* Patient is breast-feeding\n* Patient has an active ulcer or inflammatory bowel disease","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Average Pain Intensity at Rest Over Days 1 to 3","description":"Pain intensity at rest was measured on a 0- to 10-point scale: 0=no pain, to 10=pain as bad as you can imagine.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.40","spread":"0.15"},{"groupId":"OG001","value":"2.46","spread":"0.15"},{"groupId":"OG002","value":"3.26","spread":"0.15"}]}]}]},{"type":"SECONDARY","title":"Average Total Daily Dose of Morphine Over Days 1 to 3","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.37","spread":"0.08"},{"groupId":"OG001","value":"5.46","spread":"0.08"},{"groupId":"OG002","value":"7.75","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Average Elicited Pain Upon Sitting Over Days 1 to 3","description":"Elicited pain upon sitting was measured on a 0- to 10-point scale: 0=no pain, to 10=pain as bad as you can imagine.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.58","spread":"0.17"},{"groupId":"OG001","value":"3.80","spread":"0.17"},{"groupId":"OG002","value":"4.71","spread":"0.17"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":144},"commonTop":["Nausea","Constipation","Pyrexia","Dizziness","Flatulence"]}}}